65,437 trials
Cutaneous Leishmaniasis
Primary: Equivalence of Efficacy Assessed by the Number of Participants With Clinical Cure — 22; 18; 5; 9 Participants
Scleroderma, Systemic · Sclerosis · Autoimmune Disease
Primary: Global Rank Composite Score (GRCS) (Month 54, ITT) — 17.0; -6.0 Sum of subject-pair comparison scores — p=0.013
Healthy Volunteers
Primary: pH of Platelets at Day 5 — 7.184; 7.414 pH
Prostatic Hyperplasia
Primary: Changes From Baseline (BL) in Total Score From the Full Men's Sexual Health Questionnaire (MSHQ) at 12 Months — -0.7; -8.7 Scores on a scale — p=<0.001
Parkinson's Disease
Primary: Mean Change From Baseline (Visit 1 Until Visit 2) to Endpoint (After Visit 2 Until Visit 3) in the Freezing of Gait Questionnaire Score. — 1.25 change in FOGQ score…
Prostate Cancer Prevention
Primary: Change of Total Urine SFN (Sulforaphane) Metabolites — 4.75; -0.02 micromolar (µM) concentrations of urina
Flatfoot
Primary: Change in Pain Intensity Measured by 100 mm Visual Analog Scale — -31.40; -34.54; -12.08 milimiters — p=<0.001
Rift Valley Fever
Primary: Safety: All Incidences of Erythema — 15; 10; 0 number of events
Tonsillectomy · Tonsillitis · Post-operative Pain
Primary: Pain Score (Pain Scores on a 0/10 Scale) — 3.07; 4.9; 1.76; 1.42 units on a scale — p=0.043
Prostate Cancer
Primary: Feasibility — 3; 3; 16; 6 Participants
Asthma
Primary: Asthma or Recurrent Wheeze in First 3 Years of Life — 98; 120; 307; 281 Participants
Fibromyalgia
Primary: Visual Analogue Scale of Pain Intensity — 6.75; 5.71; 5.13; 6.19 Units on a scale
Hematopoietic Organs; Disorder
Primary: Number of Lactobacillus Plantarum Bacteremia Infections — 0 Number of infections
Solid Tumor · Liver Metastases
Primary: Local Control Rate — 77 percentage of participants
Metastatic Breast Cancer
Primary: Axons With Abnormal Morphology — 52; 82; 2; NA percentage of axons